DeveloGen AG

Development of therapies for diabetes and obesity based on stem cell research and phenotype-first genomics.

DeveloGen is a drug discovery company developing novel therapies for metabolic disorders, such as obesity and diabetes, based on extensive experience using model organisms and elucidating mechanisms involved in stem cell differention. DeveloGen started operations in 1998. A second product line is focused on harnessing key developmental control genes involved in stem cell differentiation and tissue regeneration. In conjunction with the approval of the merger with Peptor, a third round of financing of 19 Million EURO was closed in May 2004.

Carsten Dehning, CFO
Cord Dohrmann, Dr., CSO
Ursula Kreuzberg, Dr., VP Clinical Development and Medical Affairs

Helmut Schuehsler, Dr. Chairman
Denise Pollard-Knight, Dr., Deputy Chairperson
George Aaron
Peter Gruss, Prof. Dr.
Otello Stampacchia

Marie-Curie-Str. 7
37079 Goettingen
Germany
Phone: +49-551-50-558-0
Fax: +49-551-50-558-588

Diabetes and obesity are multi-metabolic diseases, with highly complex and interwoven biochemical pathways. DeveloGen’s answer lies in a technology platform built on two stem cells and phenotype-first genomics. The company is focused on the research and development of innovative treatments for type 1 diabetes as well as for type 2 diabetes, obesity and metabolic syndrom.
DeveloGen owns or is the exclusive licensee of more than 90 European, U.S. and other foreign patents and patent applications, including 17 issued patents.

DiaPep277™ is in the late stages of Phase 2 clinical trials for the treatment of type 1 diabetes; Somatoprim™ has completed preclinical development and is planned to enter Phase 2 clinical trials for the treatment of diabetic nephropathy in early 2005.

The following section contains a selection of the company’s most relevant patents. For comprehensive patent information please refer to the espacenet databases.